Hyperpolarized 13C MRS in prostate cancer: Wilson and Kurhanewicz identify metabolic shifts seen in cancer that may be exploited for diagnosis, with a special focus on agents and platforms developed for hyperpolarized 13C MR spectroscopy.
Page 1567
Clinical readiness of quantitative SPECT: Liu and Sinusas look at the promise and challenges associated with practical assessment of absolute myocardial perfusion with dynamic SPECT imaging.
Page 1573
Diagnostic imaging in NETs: Mansi and Cuccurullo offer perspective on PET/CT with DOTA peptides in diagnosis and staging of patients with neuroendocrine tumors and preview a related article in this issue of JNM.
Page 1576
PET/CT in young breast cancer patients: Riedl and colleagues retrospectively evaluate the utility of 18F-FDG PET/CT staging in a group of asymptomatic breast cancer patients younger than 40 years of age.
Page 1578
PET and NSCLC survival: Huang and colleagues explore the value of standardized uptake values and metabolic tumor volumes on 18F-FDG PET/CT in predicting survival in locally advanced non–small cell lung cancer during early stages of concurrent chemoradiotherapy.
Page 1584
Improving DLBCL prognosis: Cerci and colleagues report on data from a multinational study of PET and risk assessment in diffuse large B-cell lymphoma, looking specifically at marrow involvement identified by staging PET and routine bone marrow biopsy for predicting outcomes.
Page 1591
NET imaging assessment: Etchebehere and colleagues compare the relative capabilities of 99mTc-HYNIC-octreotide SPECT/CT, 68Ga-DOTATATE PET/CT, and whole-body diffusion-weighted MR imaging in patients with neuroendocrine tumors.
Page 1598
Tryptophan uptake in nontumoral brain: Kamson and colleagues investigate clinical correlates of tryptophan metabolic abnormalities in the nontumoral hemisphere of glioma patients using α-11C-methyl-l-tryptophan PET.
Page 1605
Amino acid–based PET in glioblastoma: Lapa and colleagues compare information provided by 18F-FET and 18F-DOPA in PET/CT imaging of patients with high-grade gliomas.
Page 1611
18F-FP-CIT PET/MR and AC: Choi and colleagues evaluate quantification of 18F-FP-CIT binding in brain PET/MR, focusing on the effects of ultrashort echo time–based attenuation correction including bone segmentation.
Page 1617
Categorizing 18F-flutemetamol PET: Thurfjell and colleagues assess a fully automated quantification method for classifying 18F-flutemetamol PET studies as negative or positive for brain amyloid.
Page 1623
Myocardial uptake suppression on PET: Demeure and colleagues investigate the efficacies of different interventions for suppressing myocardial 18F-FDG uptake in PET/CT detection of arterial atherosclerotic plaque inflammation.
Page 1629
212Pb radioimmunotherapy: Meredith and colleagues report on the safety, distribution, pharmacokinetics, immunogenicity, and tumor response of intraperitoneal 212Pb-TCMC-trastuzumab in patients with human epidermal growth factor receptor type 2–expressing malignancy.
Page 1636
Fat-MR–constrained PET reconstruction: Prevrhal and colleagues describe potential improvements in 18F-FDG PET image quality using a technique to constrain PET image reconstruction to low-fat regions, with the rationale that fatty tissue metabolism is low in glucose consumption.
Page 1643
Targeting neuropeptide receptors in tumors: Morgat and colleagues provide an educational overview of the biology and roles of bombesin, neurotensin, and neuropeptide-Y receptor systems that offer high potential in the field of nuclear oncology.
Page 1650
47Sc radionuclide therapy: Müller and colleagues investigate the suitability of 47Sc for therapy in a preclinical setting using a novel DOTA-folate conjugate with an albumin-binding entity, with promise for combined 44Sc/47Sc PET imaging and radionuclide therapy.
Page 1658
SPECT and PET in irradiated HNSCC: van Dijk and colleagues visualize changes in systemically accessible epidermal growth factor receptor with 111In-cetuximab-F(ab′)2 SPECT before and after radiotherapy for head and neck squamous cell carcinoma, with simultaneous 18F-FDG PET uptake evaluation.
Page 1665
PET estimation of ALA-induced PpIX: Suzuki and colleagues characterize the properties of 11C-labeled 5-aminolevulinic acid analog as a PET tracer to estimate protoporphyrin IX accumulation in tumors.
Page 1671
99mTc-cAbVCAM1-5 imaging: Broisat and colleagues assess the imaging sensitivity of this single-domain antibody fragment directed against mouse or human vascular cell adhesion molecule 1, with potential for detection of inflamed atherosclerotic lesions.
Page 1678
Dynamic SPECT absolute MBF: Wells and colleagues evaluate the measurement of myocardial blood flow using a multipinhole dedicated cardiac SPECT camera in a pig model of rest and transient occlusion at stress with 3 common tracers: 201Tl, 99mTc-tetrofosmin, and 99mTc-sestamibi.
Page 1685
hCTR1 as a novel imaging reporter gene: Kim and colleagues evaluate the potential for use of the human copper transporter 1 gene as a new reporter gene for tracking targeted delivery in vivo with PET using 64CuCl2.
Page 1692
oxLDL and macrophage 18F-FDG uptake: Lee and colleagues explore the effect of oxidized low-density lipoprotein on macrophage 18F-FDG uptake and investigate underlying molecular mechanisms, including the roles of hypoxia-inducible factor-1α and reactive oxygen species.
Page 1699
PET/NIR fluorescent tumor targeting: Pérez-Medina and colleagues describe the development of an 89Zr-based labeling strategy for liposomal nanoparticles that accumulate in tumors, with potential for integration into simultaneous PET and near-infrared imaging agents.
Page 1706
Adenosine 2A PET in rhesus monkeys: Barret and colleagues detail the development of a new 18F-labeled adenosine 2A PET radiotracer and explore relationships between plasma levels and A2A occupancy by preladenant and tozadenant in nonhuman primates.
Page 1712
Improved GRP receptor antagonists: Gourni and colleagues determine whether and how N-terminal modulations improve the affinity and pharmacokinetics of radiolabeled gastrin-releasing peptide receptor antagonists.
Page 1719
Imaging reactivation tuberculosis: Murawski and colleagues present a novel mouse model simulating the evolution of tuberculosis infection and reactivation disease, with implications for the use of serial 18F-FDG imaging in the study of pathogenesis and evaluation of novel therapeutics.
Page 1726
σ-receptor imaging in porcine brain: Brust and colleagues use the σ-receptor–specific agent 18F-fluspidine in swine to investigate the in vivo kinetics of the (R)-(+)- and (S)-(–)-enantiomers to identify their potential for imaging in humans.
Page 1730
PET in muscle denervation: Lee and colleagues explore the extent of glucose hypermetabolism in denervated muscle and investigate the feasibility of 18F-FDG PET imaging for detection of muscle denervation in a rat model.
Page 1737
- © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
Jump to section
Related Articles
Cited By...
- No citing articles found.